SEC Form 4 · accession 0000899243-16-025822
Seres Therapeutics, Inc. · MCRB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michele Trucksis
Officer — Chief Medical Officer and EVP
Period of report
Jul 27, 2016
Accepted (ET)
Jul 28, 2016 · 6:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001609809
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 27, 2016 | M | 38,064 | $15.77 | A | 38,064 | D | |
| Common StockF2 | Jul 27, 2016 | S | 38,064 | $35.1385 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $15.77 | Jul 27, 2016 | M | 38,064 | A | — | Mar 24, 2025 | Common Stock | 38,064 | 301,060 | D |
Explanation of responses
- F1The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person on February 26, 2016.
- F2The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $35.10 to $35.25. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3The option vested as to 25% of the shares on January 15, 2016. The remainder of the shares will vest in 12 equal quarterly installments thereafter.